Baxter, Halozyme win FDA OK for HyQvia

The FDA late on 12 September approved Baxter's HyQvia's (immune globulin infusion 10% (human)/recombinant human hyaluronidase), a subcutaneous treatment for adults with primary immunodeficiency, a group of more than 175 disorders in which part of the body's immune system is missing or does not function properly.